NBC News
Regeneron will seek U.S. approval for its Covid-19 antibody cocktail as a preventative treatment after a trial showed it helped reduce the risk of symptomatic infections in households where someone else is ill, the U.S. drugmaker said on Monday. REGEN-COV, as the combination shot of casirivimab and imdevimab is called, reduced the overall risk of progressing to symptomatic Covid-19 by 31 percent, and by 76 percent after the third day. The trial also demonstrated that it shortened symptom duration and markedly lowered viral levels, Regeneron said in a statement.